WO2006068826A3 - 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors - Google Patents

2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors Download PDF

Info

Publication number
WO2006068826A3
WO2006068826A3 PCT/US2005/044166 US2005044166W WO2006068826A3 WO 2006068826 A3 WO2006068826 A3 WO 2006068826A3 US 2005044166 W US2005044166 W US 2005044166W WO 2006068826 A3 WO2006068826 A3 WO 2006068826A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
pyrimidinyl
pyrazolopyridine
kinase inhibitors
erbb kinase
erbb
Prior art date
Application number
PCT/US2005/044166
Other languages
French (fr)
Other versions
WO2006068826A2 (en )
Inventor
Scott Howard Dickerson
Holly Kathleen Emerson
Philip Anthony Harris
Robert Dale Hubbard
Douglas Mccord Sammond
Kirk Lawrence Stevens
David Edward Uehling
Alex Gregory Waterson
Joseph W Wilson
Original Assignee
Scott Howard Dickerson
Holly Kathleen Emerson
Philip Anthony Harris
Robert Dale Hubbard
Douglas Mccord Sammond
Smithkline Beecham Corp
Kirk Lawrence Stevens
David Edward Uehling
Alex Gregory Waterson
Joseph W Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
PCT/US2005/044166 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors WO2006068826A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US63792804 true 2004-12-21 2004-12-21
US60/637,928 2004-12-21
US70907905 true 2005-08-17 2005-08-17
US60/709,079 2005-08-17

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11721504 US7812022B2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
EP20050853157 EP1828185B1 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
DE200560014382 DE602005014382D1 (en) 2004-12-21 2005-12-06 2-pyrimidinyl-pyrazolopyridine erbB kinase inhibitors
JP2007546747A JP5132319B2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitor

Publications (2)

Publication Number Publication Date
WO2006068826A2 true WO2006068826A2 (en) 2006-06-29
WO2006068826A3 true true WO2006068826A3 (en) 2006-10-05

Family

ID=36588699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044166 WO2006068826A3 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1828185B1 (en)
JP (1) JP5132319B2 (en)
DE (1) DE602005014382D1 (en)
ES (1) ES2325035T3 (en)
WO (1) WO2006068826A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
WO2006081332A1 (en) * 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
ES2421450T3 (en) * 2005-12-05 2013-09-02 Glaxosmithkline Llc 2-pyrimidinyl-pyrazolopyridines ErbB kinase inhibitor
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008129070A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
EP2265607B1 (en) 2008-02-15 2016-12-14 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
JP2012528175A (en) * 2009-05-27 2012-11-12 アボット・ラボラトリーズAbbott Laboratories Pyrimidine inhibitors of the kinase activity
WO2010138575A1 (en) * 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
WO2011053476A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
KR20130002371A (en) 2010-02-18 2013-01-08 알미랄, 에스.에이. Pyrazole derivatives as jak inhibitors
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
CA2787427C (en) 2010-03-05 2017-10-10 Sanofi Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
EP2402336A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2736895B1 (en) * 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN105164124B (en) * 2012-11-19 2017-03-15 诺华股份有限公司 For the treatment of parasitic diseases the compounds and compositions
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053942A1 (en) * 2000-08-22 2004-03-18 Alberti Michael John Fused pyrazole derivatives bieng protein kinase inhibitors
US6727256B1 (en) * 1998-01-12 2004-04-27 Smithkline Beecham Corporation Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727256B1 (en) * 1998-01-12 2004-04-27 Smithkline Beecham Corporation Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US20040053942A1 (en) * 2000-08-22 2004-03-18 Alberti Michael John Fused pyrazole derivatives bieng protein kinase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Also Published As

Publication number Publication date Type
DE602005014382D1 (en) 2009-06-18 grant
JP5132319B2 (en) 2013-01-30 grant
EP1828185B1 (en) 2009-05-06 grant
ES2325035T3 (en) 2009-08-24 grant
WO2006068826A2 (en) 2006-06-29 application
JP2008524220A (en) 2008-07-10 application
EP1828185A2 (en) 2007-09-05 application

Similar Documents

Publication Publication Date Title
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2005007085A3 (en) Pyrazolo pyrimidine derivatives and methods of use thereof
WO2008127226A3 (en) P13 kinase antagonists
WO2007079164A3 (en) Protein kinase inhibitors
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2004074244A3 (en) Pyrimidine compounds
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2007023115A3 (en) P38 map kinase inhibitors and methods for using the same
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
WO2006101977A3 (en) Pyrimidine compounds and methods of use
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
WO2006041773A3 (en) Lactam compounds useful as protein kinase inhibitors
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2011090760A4 (en) Heteroaryl compounds and uses thereof
WO2007011962A3 (en) Treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11721504

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005853157

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007546747

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005853157

Country of ref document: EP